



AN ELSEVIER JOURNAL

Bioorganic & Medicinal Chemistry

The International Journal for Research at the Interface
of Chemistry and Biology



Editor-in-Chief
DAVID WONG

Available online at
 ScienceDirect
www.sciencedirect.com

BIOORGANIC & MEDICINAL CHEMISTRY

Editor-in-Chief: **Professor Chi-Huey Wong**

Department of Chemistry, BCC 338, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
Facsimile: (1) 858 784 2409

American Regional Editor: Professor K. D. Janda, The Scripps Research Institute, Department of Chemistry, The Skaggs Institute for Chemical Biology, The Worm Institute of Research & Medicine, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
Facsimile: (1) 858 784 2595

Japanese Regional Editor: Professor Y. Hashimoto, Institute of Molecular & Cellular Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan
Facsimile: (81) 3 5841 8495

European Regional Editor: Professor H. Waldmann, Department of Chemical Biology, Max-planck-Institut für Molekulare Physiologie, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany
Facsimile: (49) 231 133 2499

EXECUTIVE BOARD OF EDITORS FOR TETRAHEDRON PUBLICATIONS

Chairman: **Professor H. Waldmann**

Editor Emeritus: **Professor H. H. Wasserman**

Professor D. L. Boger, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

Professor S. G. Davies, Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Mansfield Road, Oxford, OX1 3TA, UK

Professor B. Ganem, Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, NY 14853-1301, USA

Professor L. Ghosez, l'Institut Européen de Chimie et de Biologie (IECB) 33607 Pessac Cedex, France

Professor Lin Guo-Qiang, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, China

Professor Y. Hashimoto, Institute of Molecular & Cellular Biosciences, The University of Tokyo, III-Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan

Professor T. Hayashi, Department of Chemistry, Faculty of Science, Kyoto University, Kyoto 606, Japan

Professor K. Janda, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

Professor S. F. Martin, Department of Chemistry and Biochemistry, University of Texas, Austin, TX 78712, USA

Professor W. B. Motherwell, Department of Chemistry, University College, 20 Gordon Street, London WC1H 0AJ, UK

Professor S. Neidle, The School of Pharmacy, Department of Pharmaceutical & Biological Chemistry, University of London, London WC1N 1AX, UK

Professor M. Shibasaki, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Professor R. J. K. Taylor, Department of Chemistry, University of York, Heslington, York YO10 5DD, UK
(Associate Editors, Dr. P. A. O'Brien and Dr. D. K. Smith)

Professor E. J. Thomas, Department of Chemistry, University of Manchester, Brunswick Street, Manchester M13 9PL, UK
(Associate Editor, Professor J. A. Joule)

Professor K. Tomioka, Graduate School of Pharmaceutical Sciences, Department of Synthetic Medicinal Chemistry, Kyoto University, Kyoto 606-8501, Japan

Professor H. Waldmann, Max-Planck-Institut für Molekulare Physiologie, Department of Chemical Biology, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany

Professor H. H. Wasserman, Department of Chemistry, Yale University, PO Box 208107, New Haven, CT 06520 8107, USA

Professor R. M. Williams, Department of Chemistry, Colorado State University, Fort Collins, CO 80523

Professor C.-H. Wong, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

Professor J. Wood, Department of Chemistry, Colorado State University, Fort Collins, CO 80523-1872

Professor Y. Yamamoto, Department of Chemistry, Faculty of Science, Tohoku University, Sendai 980-8578, Japan
(Associate Editor, Professor M. Hirama)

Professor S. Z. Zard, Laboratoire de Synthèse Organique, Ecole Polytechnique, F-91128, Cedex, France
(Associate Editor, Dr. B. Sire)

BOARD OF CONSULTING EDITORS

P. S. Anderson, Wilmington, DE

K-H. Altmann, Zürich

P. G. Baraldi, Ferrara

C. F. Barbas, III, La Jolla, CA

J. K. Barton, Pasadena, CA

C. Bertozzi, Berkeley, CA

R. C. Breslow, New York, NY

T. C. Bruice, Santa Barbara, CA

A. R. Chamberlin, Irvine, CA

E. J. Corey, Cambridge, MA

B. Cravatt, La Jolla, CA

S. J. Danishefsky, New York, NY

P. B. Dervan, Pasadena, CA

A. Eschenmoser, Zürich

J.-M. Fang, Taipei

A. R. Fersht, Cambridge

D. M. Floyd, Princeton, NJ

G. I. Georg, Minneapolis, MN

A. Gianni, Leipzig

B. Giese, Basel

P. Gmeiner, Erlangen

H. B. Gray, Pasadena, CA

G. L. Grunewald, Lawrence, KS

P. Herrling, Basel

D. Hilvert, Zürich

L. C. Hsieh-Wilson, Pasadena, CA

W. L. Jorgensen, New Haven, CT

A. R. Katritzky, Gainesville, FL

J. A. Katzenellenbogen, Urbana, IL

J. Kelly, La Jolla, CA

P. Krosgaard-Larsen, Copenhagen

R. A. Lerner, La Jolla, CA

H. Liu, Austin, TX

A. McKillop, Northumberland

R. Metternich, Berlin

S. Mignani, Vitry-sur-Seine

L. A. Mitscher, Lawrence, KS

K. C. Nicolaou, La Jolla, CA

H. L. Pearce, Indianapolis, IN

C. D. Poulter, Salt Lake City, UT

J. Rebek, Jr, La Jolla, CA

B. Samuelsson, Stockholm

J. Saunders, San Diego, CA

S. L. Schreiber, Cambridge, MA

P. G. Schultz, La Jolla, CA

P. Seeburger, Zürich

O. Seitz, Berlin

K. Shokat, San Francisco, CA

R. Silverman, Evanston, IL

J. Stubbe, Cambridge, MA

C. T. Supuran, Firenze

G. L. Verdine, Cambridge, MA

S. Walker, Cambridge, MA

C. T. Walsh, Boston, MA

P. A. Wender, Stanford, CA

G. Whitesides, Cambridge, MA

R. V. Wolfenden, Chapel Hill, NC

PUBLISHED TWICE MONTHLY

Orders, claims, and product enquiries: Please contact the Regional Sales Office nearest you. **St. Louis:** Elsevier, Customer Service Department, 11830 Westline Industrial Drive, St. Louis, MO 63146-3313, USA; phone: (877) 839 7126 [toll free within the USA]; (+1) (314) 453 7076 [outside the USA]; fax: (+1) (314) 523 5153; e-mail: JournalCustomerService-usa@elsevier.com. **Amsterdam:** Elsevier, Customer Service Department, PO Box 211, 1000 AE Amsterdam, The Netherlands; phone: (+31) (20) 4853757; fax: (+31) (20) 4853432; e-mail: JournalsCustomerServiceEMEA@elsevier.com. **Tokyo:** Elsevier, Customer Service Department, 4F Higashi-Azabu, 1-Chome Bldg., 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: JournalsCustomerServiceJapan@elsevier.com. **Singapore:** Elsevier, Customer Service Department, 3 Killiney Road, #08-01 Winsland House I, Singapore 239519; phone: (+65) 63490222; fax: (+65) 67331510; e-mail: JournalsCustomerServiceAPAC@elsevier.com.



Bioorganic & Medicinal Chemistry Vol. 17, No. 2, 2009


Contents

REVIEW

Current perspective of TACE inhibitors: A review

pp 444–459

Shirshendu DasGupta, Prashant R. Murumkar, Rajani Giridhar, Mange Ram Yadav*




ARTICLES

Inhibition of the PCAF histone acetyl transferase and cell proliferation by isothiazolones

pp 460–466


Frank J. Dekker*, Massimo Ghizzoni, Nanette van der Meer, Rosalina Wisastra, Hidde J. Haisma



Synthesis of isothiazol-3-one derivatives as inhibitors of histone acetyltransferases (HATs)

pp 467–474


Stephen Gorsuch, Vassilios Bavetsias, Martin G. Rowlands, G. Wynne Aherne, Paul Workman, Michael Jarman, Edward McDonald*



Synthesis of novel 1,4-benzoxazin-3-one derivatives as inhibitors against tyrosine kinases

pp 699–708


Takahiro Honda*, Takahiro Terao, Hiroyuki Aono, Masakazu Ban



Structure–activity relationships of lipopolysaccharide sequestration in guanylylhydrazone-bearing lipopolyamines

pp 709–715


Wenyan Wu, Diptesh Sil, Michal L. Szostak, Subbalakshmi S. Malladi, Hemamali J. Warshakoon, Matthew R. Kimbrell, Jens R. Cromer, Sunil A. David*



Synthesis, biological evaluation and quantitative structure-activities relationship of flavonoids as vasorelaxant agents

pp 716–726

Xiaowu Dong, Tao Liu, Jingying Yan, Peng Wu, Jing Chen, Yongzhou Hu*




A series of flavonoid derivatives were designed, synthesized as vasorelaxant agents. Some were found to possess potent vasorelaxant activity. CoMFA analysis was carried out, and a statistically reliable QSAR model ($r^2=0.872$ and $q^2=0.496$) was established.

Ceramicines B–D, new antiplasmodial limonoids from *Chisocheton ceramicus*

pp 727–730

Khalit Mohamad, Yusuke Hirasawa, Marc Litaudon, Khalijah Awang, A. Hamid A. Hadi, Koichi Takeya, Wiwied Ekasari, Aty Widnyaruyanti, Noor Cholies Zaini, Hiroshi Morita*



COVER

Histone acetylation plays an important role in the regulation of gene transcription. Chromatin with a low histone acetylation level is condensed due to charge-charge interactions between the positively charged histones and the negatively charged DNA. Acetylation reduces the charge-charge interactions between the histones and the DNA and results in relaxation of the chromatin and activation of gene transcription. Recent discoveries indicate that multiple subtypes of histone acetyl transferases exist. Small molecule inhibitors of histone acetyl transferases provide tools for pharmacological studies and ultimately provide starting points for drug discovery. This issue reports studies by Dekker *et al.* and Gorsuch *et al.* on histone acetyl transferase inhibitors with an isothiazolones core structure. [Dekker, F. J.; Ghizzoni, M.; van der Meer, N.; Wisastra, R.; Haisma, H. J. *Bioorg. Med. Chem.* **2009**, *17*, 459; Gorsuch, S.; Bavetsias, V.; Rowlands, M. G.; Aherne, G. W.; Workman, P.; Jarman, M.; McDonald, E. *Bioorg. Med. Chem.* **2009**, *17*, 466.]

Available online at

 ScienceDirect
www.sciencedirect.com

Indexed/Abstracted in: Beilstein, Biochemistry & Biophysics Citation Index, CANCERLIT, Chemical Abstracts, Chemistry Citation Index, Current Awareness in Biological Sciences/BIOBASE, Current Contents: Life Sciences, EMBASE/Excerpta Medica, MEDLINE, PASCAL, Research Alert, Science Citation Index, SciSearch, TOXFILE



ELSEVIER

ISSN 0968-0896



Ceramicines B–D, new antiplasmodial limonoids from *Chisocheton ceramicus*

Khalit Mohamad^{a,b}, Yusuke Hirasawa^a, Marc Litaudon^c, Khalijah Awang^d, A. Hamid A. Hadi^d, Koichi Takeya^e, Wiwied Ekasari^f, Aty Widyawaruyanti^f, Noor Cholies Zaini^f, Hiroshi Morita^{a,*}

^a Faculty of Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142-8501, Japan

^b Department of Pharmacy, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur, Malaysia

^c Institut de chimie des Substances Naturelles, CNRS, 91198 Gif-sur-Yvette, France

^d Department of Chemistry, Faculty of Science, University Malaya, 50603 Kuala Lumpur, Malaysia

^e Tokyo University of Pharmaceutical and Life Science, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan

^f Faculty of Pharmacy, Airlangga University, Jalan Dharmawangsa Dalam, Surabaya 60286, Indonesia

ARTICLE INFO

Article history:

Received 10 September 2008

Revised 15 November 2008

Accepted 18 November 2008

Available online 24 November 2008

Keywords:

Limonoids

Chisocheton ceramicus

Ceramicines B–D

Antiplasmodial activity

ABSTRACT


Three new limonoids, ceramicines B–D (**1–3**), have been isolated from the bark of *Chisocheton ceramicus*. Structures and stereochemistry of **1–3** were fully elucidated and characterized by 2D NMR analysis. Ceramicines exhibited a moderate antiplasmodial activity.

© 2008 Elsevier Ltd. All rights reserved.

1. Introduction

Limonoids, highly oxidative unique secondary metabolites obtained from Meliaceae are produced by a unique biosynthetic route through tetranortriterpenoid nucleus.^{1,2} Insecticidal, insect anti-feedant, antibacterial, antifungal, antimalarial, anticancer, and antiviral activities have been reported for many limonoids.³ Especially, malaria caused by parasites of the genus *Plasmodium* is one of the leading infectious diseases in many tropical and some temperate regions.⁴ The emergence of widespread chloroquine-resistant and multiple-drug-resistant strains of malaria parasites leads to the need for the development of new therapeutic agents against malaria.⁵

Recently, we have isolated cassiarin A with an unprecedented tricyclic skeleton and a potent antiplasmodial activity from the leaves of *Cassia siamea*.⁶ Previous investigations on limonoids from Meliaceae have led to the isolation of several unique tetranortriterpenoids.⁷ In continuation of our antiplasmodial research on *Chisocheton ceramicus* belonging to Meliaceae family, we have isolated three new limonoids, ceramicines B–D (**1–3**) together with ceramicine A (**4**),^{7b} which showed a moderate antiplasmodial activity. Herein, we report the structure elucidation and antiplasmodial activity of ceramicines B–D (**1–3**) from *C. ceramicus*.



1.1. Structures of ceramicines B–D (**1–3**)

The crude ethanol extract of bark was partitioned between CHCl_3 , *n*-BuOH, and water. Chromatographic purification of the chloroform soluble fraction by a silica gel column (hexane/EtOAc and toluene/EtOAc solvent system) led to isolation of three new limonoids, ceramicines B (**1**, 147.4 mg, 0.074% yield), C (**2**,

* Corresponding author. Tel./fax: +81 3 5498 5778.

E-mail address: moritah@hoshi.ac.jp (H. Morita).

44.4 mg, 0.022% yield), and D (**3**, 15.0 mg, 0.0075% yield), together with ceramicine A.^{7b}

Ceramicine B (**1**, $[\alpha]_D^{20} +30$ (c 1.0, CHCl₃)) was obtained as a colorless solid and was revealed to have the molecular formula C₂₆H₃₂O₄, by HRESITOFMS [*m/z* 409.2370 (M+H)⁺, Δ -0.9 mmu]. IR absorptions implied the presence of an α,β-unsaturated ketone (1669 cm⁻¹) and a hydroxyl (3535 cm⁻¹) groups. UV spectrum (219 nm) indicated the presence of an unsaturated carbonyl group. ¹H and ¹³C NMR data (Tables 1 and 2, respectively) revealed 26 carbon resonances due to one carbonyl, two sp² quaternary carbons, four sp³ quaternary carbons, six sp² methines, five sp³ methines, four sp³ methylenes, and four methyls. Among them, three sp³ carbons (δ_C 72.5, 73.8, and 79.8) and two sp² methines (δ_C 139.7 and 142.6) were ascribed to those bearing an oxygen atom.

Five partial structures **a** (from C-2 to C-3), **b** (from C-5 to C-7), **c** (from C-9, C-11 to C-12), **d** (from C-15 to C-17), and **e** (from C-22 to C-23) were deduced from ¹H-¹H COSY analysis of **1** in CDCl₃ (Fig. 1). The presence of an enone group in ring A was supported by HMBC correlations as shown in Figure 1. HMBC correlations for H-3 and H₃-19 of C-1 (δ_C 202.9), for H₃-29 of C-5 (δ_C 47.7), and for H-7, H₃-19, and H₃-30 of C-9 (δ_C 35.9) gave rise to the connectivity of partial structures **a**, **b**, and **c** through C-4, C-8, and C-10 atoms. Connection between partial structures **c** and **d** could be assigned by HMBC correlations for H₃-18 of C-12 (δ_C 33.1), C-13 (δ_C 47.0), C-14 (δ_C 159.8), and C-17 (δ_C 51.9). The presence of a β-furyl ring at C-17 was also assigned by the HMBC correlations as shown in Figure 1. In addition, HMBC correlations for H-7 and H₂-28 of C-6 (δ_C 73.8) indicated the presence of a tetrahydrofuran ring at C-4–C-6 and C-28. Thus, ceramicine B (**1**) was concluded to be a new limonoid possessing cyclopenta[*a*]phenanthren ring system with a β-furyl ring at C-17 and a tetrahydrofuran ring.

The relative stereochemistry of **1** was elucidated by ROESY correlations as shown in computer-generated 3D drawing (Fig. 2). ROESY correlations of H-6/H_b-28, H₃-19, and H₃-30, H-7/H-15, and H-12/H-17 together with the ³J proton coupling constants (³J_{H-5/H-6} = 12.4 Hz and ³J_{H-6/H-7} = 3.8 Hz) suggested that each of H-6, H-7, and H-17 adopts a β-configuration. Furthermore, the α configurations of H-5 and H-9 was indicated by ROESY correlation of H-5/H-9.

Table 1
¹H NMR data [δ_H (J, Hz)] of ceramicines B–D (**1–3**) in CDCl₃ at 300 K

	1	2	3
2	5.83 (d, 9.6 Hz)	5.82 (d, 9.6 Hz)	5.73 (d, 9.6 Hz)
3	6.95 (d, 9.6 Hz)	6.95 (d, 9.6 Hz)	6.91 (d, 9.6 Hz)
5	2.73 (d, 12.4 Hz)	2.69 (d, 12.4 Hz)	2.59 (d, 12.4 Hz)
6	4.28 (dd, 12.4, 3.8 Hz)	4.28 (dd, 12.4, 3.8 Hz)	4.19 (dd, 12.4, 3.8 Hz)
7	4.23 (d, 3.8 Hz)	4.25 (d, 3.8 Hz)	4.10 (d, 3.8 Hz)
9	2.40 m	2.61 m	2.26 m
11a	2.52 m	2.48 m	2.40 m
11b	1.80 m	2.29 m	1.69 m
12a	1.89 m	5.13 m	1.81 m
12b	1.60 m		1.60 m
15	5.59 br s	5.69 m	5.47 br s
16a	2.55 m	2.57 m	2.53 m
16b	2.40 m	2.43 m	2.25 m
17	2.85 m	3.04 m	2.76 m
18	0.82 s	1.08 s	0.79 s
19	1.17 s	1.16 s	1.07 s
21	7.25 s	7.14 s	
22	6.29 (d, 1.6 Hz)	6.23 (d, 1.6 Hz)	7.21 (dd, 1.8, 1.8 Hz)
23	7.37 (d, 1.6 Hz)	7.28 (d, 1.6 Hz)	4.77 (br s)
28a	3.63 (d, 7.3 Hz)	3.63 (d, 7.3 Hz)	3.54 (d, 7.3 Hz)
28b	3.79 (d, 7.3 Hz)	3.79 (d, 7.3 Hz)	3.69 (d, 7.3 Hz)
29	1.34 s	1.33 s	1.25 s
30	1.13 s	1.13 s	1.03 s
3'		1.76 s	
4'		5.86, 5.47 (s)	

Table 2
¹³C NMR data (δ_C) of ceramicines B–D (**1–3**) in CDCl₃ at 300 K

	1	2	3
1	202.9	202.4	203.3
2	130.2	130.0	129.8
3	151.0	151.9	151.2
4	41.9	41.8	41.7
5	47.7	47.6	47.4
6	73.8	73.7	73.7
7	72.5	72.0	72.1
8	47.2	46.5	46.9
9	35.9	36.5	35.3
10	47.2	47.1	47.1
11	17.7	26.8	17.4
12	33.1	77.8	32.7
13	47.0	51.6	47.1
14	159.8	156.5	158.9
15	120.4	122.7	120.0
16	34.3	36.5	33.8
17	51.9	50.6	50.6
18	21.5	16.0	21.3
19	14.3	14.1	14.0
20	124.5	124.3	133.5
21	139.7	140.3	174.8
22	111.0	111.7	147.1
23	142.6	141.2	70.3
28	79.8	79.8	79.5
29	20.1	20.1	19.8
30	26.0	26.5	25.9
1'		167.1	
2'		136.4	
3'		18.0	
4'		125.9	




Figure 1. Selected 2D NMR correlations for ceramicine B (**1**).




Figure 2. Selected ROESY correlations for ceramicine B (**1**).

HRESITOFMS data [*m/z* 515.2397 (M+Na)⁺, Δ -1.3 mmu] of ceramicine C (**2**, $[\alpha]_D^{20} +47$ (c 1.0, CHCl₃)) established the molecular




Figure 3. Selected 2D NMR correlations for ceramicine C (2).

formula to be $C_{30}H_{36}O_6$, which was larger than that of ceramicine B (1) by a $C_4H_4O_2$ unit. 1H and ^{13}C NMR data (Tables 1 and 2) of 2 were analogous to those of 1, although H-12 (δ_H 5.13) and C-12 (δ_C 77.8) bearing an oxygen atom were observed for 2. The presence of methacrylic acid (δ_H 1.76, 5.47, and 5.86; δ_C 18.0, 125.9, 136.4, and 167.1) at C-12 was confirmed by HMBC correlations for H₃-3' and H-12 of C-1' (δ_C 167.1) and H₂-4' of C-1' and C-3' (δ_C 18.0).

The gross structure of 2 was elucidated by 2D NMR (1H - 1H COSY, HMQC, and HMBC) data shown in Figure 3. Analysis of ROESY spectrum (Fig. 4), suggested that the relative stereochemistry of H-12 and H-17 to be β through correlations among H-12, H-17, and H₃-30.

Ceramicine D (3), colorless amorphous solid, $[\alpha]_D^{20} +38$ (c 1.0, $CHCl_3$), was shown to have the molecular formula of $C_{26}H_{32}O_5$ by HRESITOFMS [m/z 425.2306, (M+H)⁺, $\Delta -2.2$ mmu], which was lar-




Figure 4. Selected ROESY correlations for ceramicine C (2).




Figure 5. Selected 2D NMR correlations for ceramicine D (3).




Figure 6. Selected ROESY correlations for ceramicine D (3).

ger than that of ceramicine B by 16 mmu. 1H and ^{13}C NMR data of 3 were analogous to those of ceramicine B, although the β -furyl ring signals for ceramicine B were lacking for 3. The presence of an α,β -unsaturated- γ -lactone ring instead of the β -furyl ring at C-17 was deduced by the 1H [δ_H 4.77 (br s, H-23) and 7.21 (dd, $J = 1.8, 1.8$ Hz, H-22)] and ^{13}C [δ_C 133.5 (C-20), 174.8 (C-21), 147.1 (C-22), and 70.3 (C-23)] signals.^[8] HMBC correlations for H-17 of C-20, C-21, and C-22 indicated the presence of β -substituted- γ -lactone ring (Fig. 5). The gross structure of 3 was elucidated by 2D NMR (1H - 1H COSY, HMQC, and HMBC) data, and the relative stereochemistry of 3 was assigned as the same as that of ceramicine B by ROESY correlations shown in Figure 6.

1.2. Antiplasmodial activity

Malaria caused by parasites of the genus *Plasmodium* is one of the leading infectious diseases in many tropical and some temperate regions.⁴ The emergence of widespread chloroquine-resistant and multiple-drug-resistant strains of malaria parasites leads to the need for the development of new therapeutic agents against malaria.⁵ Ceramicine B (1) showed a potent in vitro antiplasmodial activity against *Plasmodium falciparum* 3D7 (IC₅₀ 1: 0.23 μ g/ml),⁹ whereas ceramicines C (2) and D (3) did a moderate activity and ceramicine A (4) did a weak activity (IC₅₀ 2, 2.38 μ g/ml; 3, 2.15 μ g/ml; 4, 44.22 μ g/ml). Ceramicines B–D (1–3) showed a weak cytotoxicity on P388 cells (IC₅₀ 15 μ g/ml for 1; 5.5 μ g/ml for 2; 27 μ g/ml for 3). These compounds belong to two groups with a tetrahydrofuran ring at C-4–C-6 and C-28 and without this function. In comparison of antiplasmodial activity among these compounds, ceramicines B (1)–D (3) with a tetrahydrofuran ring showed a potent activity, whereas ceramicine A (4) without this function exhibited a relatively weak activity.

2. Experimental

2.1. General methods

1H and 2D NMR spectra were recorded on a 400 MHz spectrometers at 300K, while ^{13}C NMR spectra were measured on a 100 MHz spectrometer. Each NMR sample of ceramicines B–D (1–3) were prepared by dissolving 3.0 mg in 250 μ l of $CDCl_3$ in 2.5 mm micro cells (Shigemi Co., Ltd) and chemical shifts were reported using residual $CDCl_3$ (δ_H 7.21 and δ_C 77.0) as an internal standard. Standard pulse sequences were employed for the 2D NMR experiments. 1H - 1H COSY, HOHAHA, and ROESY spectra were measured with spectral widths of both dimensions of 4800 Hz, and 32 scans with two dummy scans were accumulated into 1 K data points for each of 256 t_1 increments. ROESY and HOHAHA spectra in the phase sensitive mode were measured with a mixing time of 800 and

30 ms, respectively. For HMQC spectra in the phase sensitive mode and HMBC spectra, a total of 256 increments of 1 K data points were collected. For HMBC spectra with Z-axis PFG, a 50 ms delay time was used for long-range C–H coupling. Zero-filling to 1K for F_1 and multiplication with squared cosine-bell windows shifted in both dimensions were performed prior to 2D Fourier transformation.

2.2. Material

The barks of *C. ceramicus* were collected at Pahang, Malaysia in 1996. The botanical identification was made by Mr. Teo Leong Eng, Faculty of Science, University of Malaya. Voucher specimens are deposited in the Herbarium of Chemistry Department, University of Malaya.

2.3. Extraction and isolation

The dried ground barks of *C. ceramicus* (200 g) were extracted successively with ethanol and the extract (10.5 g) was partitioned with 10% aq MeOH and CHCl_3 . The CHCl_3 -soluble materials were subjected to a silica gel column (hexane/EtOAc, 1:0 \rightarrow 0:1), in which a fraction eluted with hexane/EtOAc (7:3) was further purified on a silica gel column with toluene/EtOAc (4:1) to afford ceramicine B (**1**, 147.4 mg, 0.074% yield) as colorless solids. The fraction eluted with hexane/EtOAc (3:2) was purified on a silica gel column with toluene/EtOAc (4:1) to obtain ceramicine C (**2**, 44.4 mg, 0.022% yield). The fraction eluted with hexane/EtOAc (2:3) was purified on a silica gel column with toluene/EtOAc (3:2) to give ceramicine D (**3**, 15 mg, 0.0075% yield).

2.3.1. Ceramicine B (1)

Colorless solid; $[\alpha]_D^{20} +30$ (c 1.0, CHCl_3); IR (KBr) ν_{max} 3535, 3457, 2969, 2927, 2862, 1720, 1669, 1457, 1387, and 1247 cm^{-1} ; UV (MeOH) λ_{max} 219 (ϵ 9300) nm; CD (MeOH) λ_{max} 340 (θ -3300) and 220 nm (θ $+30,800$); ^1H and ^{13}C NMR data (Tables 1 and 2); HRESITOFMS m/z 409.2370 (M+H; calcd for $\text{C}_{26}\text{H}_{32}\text{O}_4$, 409.2379).

2.3.2. Ceramicine C (2)

Colorless solid; $[\alpha]_D^{20} +47$ (c 1.0, CHCl_3); IR (KBr) ν_{max} 3448, 2932, 1711, 1677, 1451, 1389, 1248, and 1160 cm^{-1} ; UV (MeOH) λ_{max} 219 (ϵ 9400) nm; CD (MeOH) λ_{max} 334 (θ -2700) and 220 nm (θ $+29600$); ^1H and ^{13}C NMR data (Tables 1 and 2); HRESITOFMS m/z 515.2397 (M+Na; calcd for $\text{C}_{30}\text{H}_{36}\text{O}_6\text{Na}$, 515.2410).

2.3.3. Ceramicine D (3)

Colorless solid; $[\alpha]_D^{20} +38$ (c 1.0, CHCl_3); IR (KBr) ν_{max} 3435, 2929, 1750, 1677, 1459, 1388, and 1249 cm^{-1} ; UV (MeOH) λ_{max} 222 (ϵ 10,000) nm; CD (MeOH) λ_{max} 338 (θ -2100) and 223 nm (θ $+17,900$); ^1H and ^{13}C NMR data (Tables 1 and 2); HRESITOFMS m/z 425.2306 (M+H; calcd for $\text{C}_{26}\text{H}_{32}\text{O}_5$, 425.2328).

2.4. Antiplasmodial activity

Human malaria parasites were cultured according to the method by Trager et al.⁹ The antimalarial activity of the isolated compounds was determined by the procedure described by Budimulja et al.¹⁰ In brief, stock solution of the samples were prepared in DMSO (final DMSO concentrations of $<0.5\%$) and were diluted to the required concentration with complete medium (RPMI-1640 supplemented with 10% human plasma, 25 mM Hepes and 25 mM NaHCO_3) until the final concentration of samples at well culture plate are: 10, 1, 0.1, 0.01, 0.001 $\mu\text{g/ml}$. The malarial parasite

P. falciparum 3D7 clone was propagated in a 24-well culture plate in the presence of a wide range of concentrations of each compound. The growth of the parasite was monitored by making a blood smear fixed with MeOH and stained with Geimsa stain. The antimalarial activity of each compound was expressed as an IC_{50} value, defined as the concentration of the compound causing 50% inhibition of parasite growth relative to an untreated control.

The percentage of growth inhibition was expressed according to following equation: Growth inhibition% = $100 - [(\text{test parasitaemia}/\text{control parasitemia}) \times 100]$. Chloroquine: $\text{IC}_{50} = 0.0061 \mu\text{g/ml}$.

2.5. Cytotoxicity

P-388 murine leukemia cells were maintained in RPMI-1640 medium supplemented with 5% fetal calf serum and kanamycin (100 $\mu\text{g/ml}$). The cells (3×10^3 cells/well) were cultured in Corning disposable 96-well plates containing 100 μl of growth medium per well and were incubated at 37 $^\circ\text{C}$ in a humidified atmosphere of 5% CO_2 . Various drug concentrations (10 μl) were added to the cultures at day one after the transplantation. At day three, 20 μl MTT solution (5 mg/ml) per well was added to each cultured medium. After a further 4 h of incubation, 100 μl of 10% SDS-0.01 N HCl solution was added to each well and the formazan crystals in each well were dissolved by stirring with a pipette. The optical density measurements were made using a micropipette reader (Tohso MPR-A4i) with a two wavelength system (550 and 700 nm). In all experiments, three replicate wells were used to determine each point.

Acknowledgments

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and grants from Tokyo Biochemical Foundation, The Open Research Center Project in Hoshi university, ScienceFund 12-02-03-2034, Ministry of Science and Technology, Malaysia, Scientific grant from Institut de chimie des Substances Naturelles, CNRS, France, and Assessment Service Unit, Faculty of Pharmacy, Airlangga University.

References and notes

- (a) Taylor, D. A. H. In Herz, W., Grisebach, H., Kirby, G. W., Eds.; Progress in the Chemistry of Organic Natural Products; Springer: New York, 1984; Vol. 45. (b) Mulholland, D.; Parel, A.; Coombes, P. H. *Curr. Org. Chem.* **2000**, *4*, 1011.
- (a) Yin, S.; Wang, X. N.; Fan, C. Q.; Liao, S. G.; Yue, J. M. *Org. Lett.* **2007**, *9*, 2353; (b) Zhang, C. R.; Yang, S. P.; Liao, S. G.; Fan, C. Q.; Wu, Y.; Yue, J. M. *Org. Lett.* **2007**, *9*, 3383; (c) Di, Y. T.; He, H. P.; Liu, H. Y.; Yi, P.; Zhang, Z.; Ren, Y. L.; Wang, J. S.; Sun, Q. Y.; Yang, F. M.; Fang, X.; Li, S. L.; Zhu, H. J.; Hao, X. J. *J. Nat. Prod.* **2007**, *70*, 1352.
- (a) Zhang, H.; Wang, X.; Chen, F.; Androurakis, X. M.; Wargovich, M. J. *Phytother. Res.* **2007**, *21*, 731; (b) Roy, A.; Saraf, S. *Biol. Pharm. Bull.* **2006**, *29*, 191; (c) Bray, D. H.; Warhurst, D. C.; Connolly, J. D.; O'Neill, M. J.; Phillipson, J. D. *Phytother. Res.* **1990**, *4*, 29.
- Wiesner, J.; Ortmann, R.; Jomaa, H.; Schlitzer, M. *Angew. Chem. Int. Ed.* **2003**, *42*, 5274.
- (a) Gelb, M. H.; Hol, W. G. *Science* **2002**, *297*, 343; (b) De Smet, P. A. G. N. *Drugs* **1997**, *54*, 801.
- Morita, H.; Oshimi, S.; Hirasawa, Y.; Koyama, K.; Honda, T.; Ekasari, W.; Indrayanto, G.; Zaini, N. C. *Org. Lett.* **2007**, *9*, 3691.
- (a) Awang, K.; Lim, C. S.; Mohamad, K.; Morita, H.; Hirasawa, Y.; Takeya, K.; Thoison, O.; Hadi, A. H. A. *Bioorg. Med. Chem.* **2007**, *15*, 5997; (b) Mohamad, K.; Hirasawa, Y.; Lim, C. S.; Awang, K.; Hadi, A. H. A.; Takeya, K.; Morita, H. *Tetrahedron Lett.* **2008**, *49*, 4276.
- Krief, S.; Martin, M.-T.; Grellier, P.; Kasenene, J.; Sevenet, T. *Antimicrob. Agents Chemother.* **2004**, *3196*.
- Trager, W.; Jensen, J. B. *Science* **1976**, *193*, 673.
- Budimulja, A. S.; Syafruddin, T. P.; Wilairat, P.; Marzuki, S. *Mol. Biochem. Parasitol.* **1997**, *84*, 137.

Bioorganic and Medicinal Chemistry

Q2 Drug Discovery
best quartile

SJR 2021
0.6

powered by scimagojr.com

also developed by scimago **SCIMAGO INSTITUTIONS RANKINGS**

SJR Scimago Journal & Country Rank

Home Journal Rankings Country Rankings Viz Tools Help About Us

Enter Journal Title, ISSN or Publisher Name

Bioorganic and Medicinal Chemistry

COUNTRY United Kingdom 	SUBJECT AREA AND CATEGORY Biochemistry, Genetics and Molecular Biology └ Biochemistry └ Clinical Biochemistry └ Molecular Biology └ Molecular Medicine Chemistry └ Organic Chemistry Pharmacology, Toxicology and Pharmaceutics └ Drug Discovery └ Pharmaceutical Science	PUBLISHER Elsevier Ltd.	H-INDEX 171
PUBLICATION TYPE Journals	ISSN 09680896, 14643391	COVERAGE 1993-2021	INFORMATION Homepage How to publish in this journal Contact

Scopus Preview

Author Search Sources Create account Sign in

Source details

Feedback > Compare sources >

Bioorganic and Medicinal Chemistry
Scopus coverage years: from 1993 to Present
Publisher: Elsevier
ISSN: 0968-0896 E-ISSN: 1464-3391

Subject area: [Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science](#) [Chemistry: Organic Chemistry](#)
[Pharmacology, Toxicology and Pharmaceutics: Drug Discovery](#) [Biochemistry, Genetics and Molecular Biology: Biochemistry](#)
[Biochemistry, Genetics and Molecular Biology: Clinical Biochemistry](#) [Biochemistry, Genetics and Molecular Biology: Molecular Medicine](#)
[Biochemistry, Genetics and Molecular Biology: Molecular Biology](#) [View less ^](#)

Source type: Journal

[View all documents >](#) [Set document alert](#) [Save to source list](#) [Source Homepage](#)

CiteScore 2021 **6.5**
SJR 2021 **0.598**
SNIP 2021 **0.903**

CiteScore CiteScore rank & trend Scopus content coverage

i Improved CiteScore methodology
CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021

6.5 = $\frac{12,621 \text{ Citations } 2018 - 2021}{1,932 \text{ Documents } 2018 - 2021}$

Calculated on 05 May, 2022

CiteScoreTracker 2022

5.0 = $\frac{7,500 \text{ Citations to date}}{1,488 \text{ Documents to date}}$

Last updated on 06 June, 2022 • Updated monthly

CiteScore rank 2021

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics └ Pharmaceutical Science	#35/171	79th
Chemistry └ Organic Chemistry	#43/192	77th
Pharmacology, Toxicology and Pharmaceutics └ Drug Discovery	#41/154	73rd
Biochemistry, Genetics and Molecular Biology └ Biochemistry	#139/425	67th
Biochemistry, Genetics and Molecular Biology └ Clinical Biochemistry	#39/115	66th
Biochemistry, Genetics and Molecular Biology └ Molecular Medicine	#65/167	61st
Biochemistry, Genetics and Molecular Biology └ Molecular Biology	#164/386	57th